Photo from wikipedia
Patients with hematologic malignancies have impaired humoral immunity secondary to their malignancy and its treatment, placing them at risk of severe coronavirus disease‐19 (COVID‐19) infection and reduced response to vaccination. Click to show full abstract
Patients with hematologic malignancies have impaired humoral immunity secondary to their malignancy and its treatment, placing them at risk of severe coronavirus disease‐19 (COVID‐19) infection and reduced response to vaccination.
Keywords:
hematologic malignancies;
vaccination;
initial booster;
covid;
seroconversion outcomes;
outcomes initial
Journal Title: Cancer
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!